Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Codeine phosphate 30 mg and paracetamol 500 mg effervescent oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Codeine phosphate 30 mg and paracetamol 500 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Dihydrocodeine tartrate 20 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Dihydrocodeine tartrate 30 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely codeine phosphate 13.5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely diphenhydramine 25 milligram and paracetamol 500 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Codeine phosphate 12.8 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Paracetamol+diphenhydramine hydrochloride 120mg/12.5mg s/f oral solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Paracetamol+promethazine hydrochloride 120mg/1.5mg/5mL color free s/f suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely domperidone (as domperidone maleate) 10 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely metoclopramide 5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Metoclopramide hydrochloride 5 mg and paracetamol 500 mg effervescent powder for oral suspension sachet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely isometheptene mucate 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Co-codamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely caffeine 65 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely caffeine 30 milligram and paracetamol 450 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Caffeine 25 mg and paracetamol 450 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Paracetamol 150 mg and sodium salicylate 100 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Acetaminophen compound preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing caffeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing dextropropoxyphene and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing dihydrocodeine tartrate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Paracetamol+caffeine 500mg/65mg soluble tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely butalbital 50 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Butalbital 50 mg and paracetamol 325 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely butalbital 50 milligram and paracetamol 650 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Butalbital 50 mg and paracetamol 650 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely caffeine 100 milligram and isometheptene mucate 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely dichloralphenazone 100 milligram and isometheptene 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Acetaminophen + dichloralantipyrine + isometheptene mucate (1:1) 325mg/100mg/65mg capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Hydrocodone bitartrate 5 mg and paracetamol 325 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Hydrocodone bitartrate 10 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Hydrocodone bitartrate 5 mg and paracetamol 500 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely hydrocodone bitartrate 5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Acetaminophen + hydrocodone bitartrate 500mg/7.5mg elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Hydrocodone bitartrate 7.5 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Hydrocodone bitartrate 5 mg and paracetamol 556 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 650 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely hydrocodone bitartrate 7.5 milligram and paracetamol 650 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Hydrocodone bitartrate 10 mg and paracetamol 660 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely hydrocodone bitartrate 7.5 milligram and paracetamol 750 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Acetaminophen + orphenadrine citrate 500mg/50mg caplets |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Paracetamol 300 mg and phenyltoloxamine citrate 20 mg and salicylamide 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Acetaminophen + phenyltoloxamine citrate 500mg/30mg caplets |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Paracetamol 500 mg and phenyltoloxamine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Paracetamol 500 mg and phenyltoloxamine citrate 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Paracetamol 650 mg and phenyltoloxamine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Paracetamol 250 mg and salicylamide 600 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing hydrocodone bitartrate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 400 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Acetaminophen 650mg/25mL liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing paracetamol and salicylamide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Acetaminophen + pentazocine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing dichloralphenazone and isometheptene and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Paracetamol |
Inferred relationship |
Some |
3 |
Product containing precisely hydrocodone bitartrate 2.5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing caffeine and isometheptene mucate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing paracetamol and phenyltoloxamine citrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Acetaminophen + alcohol + codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Acetaminophen + orphenadrine citrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing paracetamol and sodium salicylate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing chlormezanone and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Acetaminophen+diphenhydramine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing butalbital and caffeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing oxycodone hydrochloride and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing butalbital and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Paracetamol |
Inferred relationship |
Some |
1 |
Isometheptene mucate+acetaminophen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing butalbital and caffeine and codeine phosphate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing methionine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Paracetamol |
Inferred relationship |
Some |
1 |
Acetaminophen + dichloralantipyrine + isometheptene mucate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Acetaminophen + chloralantipyrine + isometheptene mucate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing paracetamol and propoxyphene napsylate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Paracetamol 160 mg chewable tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing paracetamol and promethazine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing paracetamol and phenyltoloxamine citrate and salicylamide |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Acetaminophen + chlorpheniramine maleate + phenylephrine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Acetaminophen + tramadol hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing metoclopramide and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing domperidone maleate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Plasma paracetamol measurement (procedure) |
Component |
False |
Paracetamol |
Inferred relationship |
Some |
2 |
Product containing caffeine and dihydrocodeine tartrate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Acetaminophen + codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Codeine phosphate 15 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely paracetamol 500 milligram/1 each conventional release effervescent oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely paracetamol 500 milligram and pseudoephedrine hydrochloride 30 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing paracetamol and pseudoephedrine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Acetaminophen 1g/sachet powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Paracetamol 250 mg orodispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Paracetamol 1g/sachet powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing clemastine fumarate and paracetamol and phenylpropanolamine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing precisely clemastine fumarate 335 microgram and paracetamol 500 milligram and phenylpropanolamine 30 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Paracetamol |
Inferred relationship |
Some |
|
Product containing chlorphenamine and paracetamol and phenylpropanolamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Paracetamol |
Inferred relationship |
Some |
3 |
Product containing chlorphenamine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Paracetamol |
Inferred relationship |
Some |
2 |